Compare SBR & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SBR | CERT |
|---|---|---|
| Founded | 1982 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Retail: Computer Software & Peripheral Equipment |
| Sector | Energy | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | N/A | 2020 |
| Metric | SBR | CERT |
|---|---|---|
| Price | $75.13 | $6.18 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $12.22 |
| AVG Volume (30 Days) | 32.6K | ★ 3.3M |
| Earning Date | 02-27-2026 | 05-04-2026 |
| Dividend Yield | ★ 6.51% | N/A |
| EPS Growth | N/A | ★ 87.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $418,838,000.00 |
| Revenue This Year | N/A | $4.26 |
| Revenue Next Year | N/A | $5.40 |
| P/E Ratio | $12.77 | ★ N/A |
| Revenue Growth | N/A | ★ 8.75 |
| 52 Week Low | $58.25 | $6.04 |
| 52 Week High | $84.39 | $15.38 |
| Indicator | SBR | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 58.30 | 29.73 |
| Support Level | $65.77 | $6.04 |
| Resistance Level | $79.86 | $11.53 |
| Average True Range (ATR) | 1.92 | 0.34 |
| MACD | 0.06 | -0.00 |
| Stochastic Oscillator | 69.05 | 5.23 |
Sabine Royalty Trust is an express trust which is formed to receive Sabine Corporation's royalty and mineral interests, including landowner's royalties, overriding royalty interests, minerals production payments and any other similar, non-participatory interests, in certain Royalty Properties. The trusts producing and proved undeveloped oil and gas royalty properties are located in Florida, Louisiana, Mississippi, New Mexico, Oklahoma, and Texas.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.